Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients

International Journal of COPD

Volumn 6, Issue 1, 2011, Pages 503-509

  Tzani, Panagiota ^a   Crisafulli, Ernesto ^b   Nicolini, Gabriele ^c   Aiello, Marina ^a   Chetta, Alfredo ^a   Clini, Enrico Maria ^b   Olivieri, Dario ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c Medical Affairs Department   (Italy)

Author keywords

Airflow obstruction; Chronic obstructive pulmonary disease; Small airways

Indexed keywords

BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; FLUTICASONE PROPIONATE PLUS SALMETEROL;

ADULT; AGED; ARTICLE; BODY PLETHYSMOGRAPHY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RESIDUAL VOLUME; TOTAL LUNG CAPACITY; TREATMENT OUTCOME;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; ALBUTEROL; ANDROSTADIENES; BECLOMETHASONE; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DYSPNEA; ETHANOLAMINES; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; GLUCOCORTICOIDS; HUMANS; ITALY; LUNG; MALE; MIDDLE AGED; PLETHYSMOGRAPHY, WHOLE BODY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESIDUAL VOLUME; TIME FACTORS; TOTAL LUNG CAPACITY; TREATMENT OUTCOME;

EID: 84862298831     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S23746     Document Type: Article

References (24)

1. GOLD Report Executive Summary. Global Strategy for Diagnosis, Management, and Prevention of COPD. December 2010. In: GOLD - Global Initiative for Chronic Obstructive Lung Disease home page (http://www. goldcopd.org/guidelines-global-strategy-for-diagnosis-management. html).
2. O'Donnell DE, Lam MIU, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:542-549.
3. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:770-777.
4. Ferguson GT. Why does the lung hyperinfate? Proc Am Thorac Soc. 2006;3(2):176-179.
5. Garcia-Rio F, Lores V, Mediano O, et al. Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. Am J Respir Crit Care Med. 2009;180(6):506-512.
6. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153:967-975.
7. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost. 2000;84(2):210-215.
8. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847-852.
9. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60(11):925-931.
10. De Backer W, Devolder A, Poli G, et al. Lung deposition of BDP/ formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010;23(3):137-148.
11. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Offcial Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5-40.
12. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85:751-758.
13. O'Donnel DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832-840.
14. Taube C, Lehnigk B, Paasch K, et al. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162:216-220.
15. Papi A, Paggiaro P, Nicolini G, Vignola AM, Fabbri LM. Beclomethasone/ formoterol vs futicasone/salmeterol inhaled combination in moderate to severe asthma. Allergy. 2007;62:1182-1188.
16. Scichilone N, Battaglia S, Sorino C, et al. Effects of extra-fne inhaled beclomethasone/formoterol on both large and small airways in asthma. Allerg y. 2010;65(7):897-902.
17. Calverley PM, Kuna P, Monsó E, et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med. 2010;104(12):1858-1868.
18. Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2(1):99-103.
19. Papi A, Paggiaro PL, Nicolini G, Vignola AM, Fabbri LM. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J. 2007;29:682-689.
20. Huchon G, Magnussen H, Chuchalin A, Dymek L, Gonod FB, Bousquet J. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med. 2009;103:41-49.
21. Calverley PMA, Anderson JA, Celli B; for the TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789.
22. Di Marco F, Milic-Emili J, Boveri B, et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J. 2003;21:86-94.
23. Sturton RG, Triflieff A, Nicholson AG, Barnes PJ. Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther. 2008;324(1):270-275.
24. Italian Registry for Clinical Trials. http://ricerca-clinica.agenziafarmaco.it/en/node/22. Accessed September 10, 2011.